As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: March 13, 2014
by Medical XPress:
When initiated soon after menopause, hormone therapy with estradiol prevented degeneration in key brain regions of women who were at heightened dementia risk, according to a new study led by Stanford University School of Medicine researchers.
The investigators also found that another type of hormone therapy, marketed under the brand name Premarin, was far less protective. Premarin is a mixture of 30-plus substances derived from the urine of pregnant mares. Estradiol—the dominant sex-steroid hormone in woman—accounts for about 17 percent of Premarin’s total content. Other Premarin components exert various endocrinological effects on different tissues.
The randomized study sought to understand the effects of continuing versus stopping hormone therapy on cerebral metabolism. It will be published March 12 in PLOS ONE. The findings indicate that hormone therapy’s neurological effect on woemn at risk for dementia depends critically on when they begin therapy and on whether they use estradiol or Premarin, said lead author Natalie Rasgon, MD, PhD, professor of psychiatry and behavioral sciences and director of the Stanford Center for Neuroscience in Women’s Health.
The researchers observed brain regions in and around the hippocampus that are associated with memory and executive function. These regions are among the earliest to show deterioration in metabolic activity in many forms of dementia, ranging from mild cognitive impairment to Alzheimer’s disease.
When women who had started an estradiol regimen within a year of menopause stayed on the regimen, metabolic activity in a number of these brain regions was preserved. But it declined significantly among those who stopped using the hormone.
Staying on Premarin, however, actually appeared to accelerate some of these brain regions’ metabolic decline. If another hormone, progestin (essentially, synthetic progesterone), was taken along with either estradiol or Premarin, it obliterated estradiol’s neurological benefit and steepened the decline seen with Premarin.
The study, while too small to give meaningful results for direct tests of cognition, was large enough to achieve a high level of statistical significance for its imaging results.
Napping for an hour in the afternoon may provide a mental boost for older adults, a new study suggests. This extra daytime sleep was linked to improved memory and ability to think clearly...
The results of recent trials that tested much-anticipated Alzheimer’s disease drugs dashed the hopes of patients with the debilitating condition. The most recent disappointment came from the large trial for solanezumab, by Eli Lilly, announced last...
Treatment with the antibiotic Rocephin (ceftriaxone) may restore brain function in areas affected by Alzheimer’s disease, according to new research. The study, “Mapping Synaptic Glutamate Transporter Dysfunction In Vivo To Regions Surrounding Aβ...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.